linjc16/ctgov huggingface dataset:
Sacroiliac Orthopedic Blocking and Cervical Spine Function

Study Overview
=================
Brief Summary
-----------------
This study seeks to determine if the correction of a sacroiliac lesion can produce a functional change in cervical spine. Reduction of a sacroiliac joint lesion may alter cervical spine function.

Conditions
-----------------
Musculoskeletal Diseases

Intervention / Treatment
-----------------
* Other: Spinal Manipulative Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Young adults currently enrolled at Logan College Exclusion Criteria: Recent cervical spine injuries or surgeries Surgical hardware in the cervical spine or pelvis Any cervical condition that would make ROM & strength testing painful.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Spinal Manipulative Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
This study seeks to determine if the correction of a sacroiliac lesion can produce a functional change in cervical spine.
Over-night Effect of Dietary Fiber on Glucose Metabolism and Satiety

Study Overview
=================
Brief Summary
-----------------
The experimental model is a semi-acute, over-night, study where the purpose is to evaluate food factors related to colonially derived regulation and satiety in healthy subjects.

Official Title
-----------------
Indigestible Carbohydrates in an Over-night Design as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety

Conditions
-----------------
Obesity, Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: High levels of indigestible carbohydrates
* Other: Low levels of indigestible carbohydrates


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal fasting blood glucose BMI 19-25 kg/m2 Exclusion Criteria: Gastrointestinal diseases Food allergies e.g. lactose-, gluten intolerance Metabolic disorder e.g. diabetes Tobacco/snuff users No antibiotic or probiotic intake 2 weeks prior and during study. Vegetarians

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: + ind. CHO<br>Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables | Other: High levels of indigestible carbohydrates<br> <br> |
| Experimental: - ind. CHO<br>Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables | Other: Low levels of indigestible carbohydrates<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Glucose, levels of glucose in blood |  | Postprandial 0-180 min after breakfast | 
| Insulin, levels of insulin in blood |  | Postprandial 0-180 min after breakfast | 
| Appetite hormones, levels of Peptide YY (PYY) in blood |  | Postprandial 0-180 min after breakfast | 
| Markers of colonic fermentation, levels of hydrogen in breath |  | Postprandial 0-180 min after breakfast | 
| Inflammation markers, levels of Interleukin-6 (IL-6) in blood |  | Postprandial 0-180 min after breakfast | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective satiety, as measured by VAS |  | Postprandial 0-180 min after breakfast |
Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis

Study Overview
=================
Brief Summary
-----------------
Dialysis patients, who decide to switch from standard dialysis (3 times 240-270 min/week) to nocturnal dialysis (3 times 480 min/week), will be followed. In parallel a control group with patients staying on standard dialysis will be followed. The study will last 30 weeks. During this period blood samples (pre- and post-dialysis: 10 times; inlet and outlet of dialyzer: 3 times) will be collected on predetermined time points. Concentration of several uremic retention solutes will be determined.

Official Title
-----------------
Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis

Conditions
-----------------
Chronic Renal Failure

Intervention / Treatment
-----------------
* Procedure: Nocturnal dialysis
* Procedure: Standard dialysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Nocturnal dialysis | Procedure: Nocturnal dialysis<br>* Switch to nocturnal dialysis (3 times 480 min/week)<br>|
| Active Comparator: 2<br>Standard dialysis | Procedure: Standard dialysis<br>* Standard dialysis (3 times 240-270 min/week)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate what is more effective for removal of uremic toxins - nocturnal versus standard dialysis? |  | 30 weeks |
DESyne in Routine Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate effectiveness and safety of DESyne in Routine Clinical Practice

Official Title
-----------------
Evaluation of Effectiveness and Safety of DESyne in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Conditions
-----------------
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: DeSyne drug eluting stent group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20 and more Intervention with DeSyne drug eluting coronary stent Agreed with written informed consent form Exclusion Criteria: Intervention with DeSyne drug eluting coronary stent and other drug eluting stent at the same time Life expectancy of 1year and under Cardiac shock

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IRIS DeSyne<br>DeSyne drug eluting stent group | Device: DeSyne drug eluting stent group<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite event rate | Death, non fatal myocardial infarction, Target Vessel Revascularization | 1year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All death |  | 5year | 
| Cardiac death |  | 5year | 
| Myocardial infarction |  | 5year | 
| Composite event of death or myocardial infarction |  | 5year | 
| Composite event of cardiac death or myocardial infarction |  | 5year | 
| Target Vessel revascularization |  | 5year | 
| Target Lesion revascularization |  | 5year | 
| Stent thrombosis | stent thrombosis as classified by an Academic Research Consortium | 5year | 
| Stroke |  | 5year | 
| Procedural success | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. | 3day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DeSyne, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease
Conventional Bronchoscopy Plus Rose Versus Electromagnetic Navigation (EMN) Plus Rose in Small Peripheral Lesions

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate if Electromagnetic navigation (ENB) in combination with rapid on site evaluation (ROSE) can improve diagnostic accuracy in those patients who fail to be diagnosed with conventional fluoroscopic assisted bronchoscopy (FBS) in combination with ROSE.

Official Title
-----------------
Comparison of the Electromagnetic Navigation System and Rapid on Site Evaluation Versus Conventional Bronchoscopy and Rapid on Site Evaluation: Improved Yield in Small Peripheral Lung Lesions(Original Investigation)

Conditions
-----------------
Lung Cancer, Secondary Lung Cancer, Benign Lung Lesions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of small peripheral lung lesions (< 3 cm) in patient suitable for surgical procedure Exclusion Criteria: patient with metastatic disease patients unfit for surgical procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 36-40 patients<br>patients with small peripheral lesions who need bronchoscopy for diagnostic purposes | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the percentages of diagnosis that can be obtained adding ENB to conventional bronchoscopy in the same patient |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ENB, FBS, coin lesions, ROSE
Acute Gastrointestinal Injury in Pediatrics

Study Overview
=================
Brief Summary
-----------------
Critically Ill children may develop acute gastrointestinal injury secondary to severe inflammation.

Detailed Description
-----------------
Data collection from enrolled subjects including profile, laboratory examinations, inflammatory markers on day 1 and day 3, nutritional support and daily calorie intake, and finally outcome of the patient

Official Title
-----------------
Acute Gastrointestinal Injury in Critically Ill Children in Pediatric Intensive Care Unit of Cipto Mangunkusumo Hospital

Conditions
-----------------
Acute Gastrointestinal Injury, Gastrointestinal Failure, Critical Illness

Intervention / Treatment
-----------------
* Other: AGI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: critically ill pediatric patients receiving care at the PICU presence of AGI (any degree) Exclusion Criteria: patients who's body weight cannot be measured

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: AGI|no intervention, only observation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PELOD-2 score | The Pediatric Logistic Organ Dysfunction (PELOD)-2 score is used to predict mortality and assess organ dysfunction. It consist of 10 components, assessing 5 organ dysfunction. The minimum score of PELOD-2 is 0 and the maximum score is 33. With the increasing organ dysfunction, the probability of death also increases. | time of AGI diagnosis, day-1 PELOD-2 score | 
| mortality | PICU mortality | days from PICU admission date up to 28 days follow-up |
Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry

Study Overview
=================
Brief Summary
-----------------
The primary objectives for the registry is to evaluate the overall incidence of serious complications or adverse events for primary implants and replacement devices, and assess the cost and time efficiency for both physicians and patients. The Registry is a multi ASC data collection registry. Data collection will occur at the time of screening, implant, and 2 weeks after implant at the time of wound check.

Official Title
-----------------
Ambulatory Surgical Center Implantable Cardioverter-Defibrillator Outcomes Registry

Conditions
-----------------
Arrhythmia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physician recommendation to receive the implant in an Ambulatory Surgical Center (ASC) Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients receiving ICD devices<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful Implantation | Patient undergoes surgery for ICD device implantation | Two-week follow-up assessment |
MightySat - Clinical Performance Comparison Study

Study Overview
=================
Brief Summary
-----------------
This study compares the performance of respiratory rate from pleth (RRp) measured with MightySat device on healthy subjects.Subjects will be asked to breathe at specific rates ranging from 5 to 30 breaths per minute.

Official Title
-----------------
MightySat - Clinical Performance Comparison Study

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: MightySat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 45 years old Physical status of ASA I or II Must be able to read and communicate in English Has signed all necessary related documents, e.g. written informed consent, confidentiality agreement Passed health assessment screening Negative pregnancy test for female subjects of child bearing potential Exclusion Criteria: Younger than 18 years old, older than 45 years old ASA physical status of III, IV, and V Subject has any medical condition which in the judgement of the investigator, renders them inappropriate for participation in the study Inability to tolerate sitting still or minimal movement for at least 30 minutes Positive pregnancy test for female subjects Refusal to take pregnancy test for women of child bearing potential Nursing female subjects Refusal of male subjects to agree to shave hair off areas where sensors will be applied (neck) Excluded at Principal Investigator's discretion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MightySat Test group<br>The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter. | Device: MightySat<br>* MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of RRp Determination | Accuracy will be determined by comparing the noninvasive respiratory rate by pleth (RRp) measurement of the MightySat to the respiratory rate (RR) reference and calculating the arithmetic root mean square error (Arms) value. In order to obtain the Arms value, the RR measurement from the reference is subtracted from the MightySat RRp measurement for a number of samples, the average of this difference is computed as the bias. The standard deviation of the differences is computed as the precision. The square root of the sum of the squares of bias and precision is computed as the Arms Error value. | approximately 30-40 minutes |
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
To assess the efficacy and safety of the Ginkgo biloba extract in patients with Knee OA.

Official Title
-----------------
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Combination Product: Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)
* Combination Product: placebo in addition to the standard treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 40-75 years old with knee OA. Grade II and Grade III according to the Kellgrenn-Lawrence (KL) grading system of radiographic OA. Exclusion Criteria: Pregnancy, breastfeeding Liver or renal problems Patient taking any drug that might interact with Ginkgo extract (eg. warfarin, etc.) patient with cardiovascular or cerebral vascular disorders, uncontrolled diabetes, allergic to ginkgo, recent surgery or hospital admission, >75 years old. Allergic or contraindicated to using NSAIDs

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ginkgo + standard<br>the patients received Ginkgo biloba extract in addition to standard treatment | Combination Product: Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)<br>* 120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily<br>* Other names: Ginko Natrol company + Dolipran+Olfen 100 SR;|
| Placebo Comparator: placebo + standard<br>the patients received a placebo in addition to the standard treatment | Combination Product: placebo in addition to the standard treatment<br>* placebo in addition to the standard treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KOOS score | 42 item questionnaire to assess pain, other symptoms, activities of daily living (ADL), sport and recreation function (Sport/Rec) and knee-related quality of life (QOL). | Changes occured : baseline , 2 weeks , 4 weeks ,and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-6 | Serum level of interleukin 6 | Changes occured: baseline , 4 weeks,and 8 weeks | 
| TNF-alpha | Serum level of tumour necrosis factor - alpha | Changes occured: baseline , 4 weeks,and 8 weeks | 
| urinary CTX-II | C-terminal telopeptide of type II collagen from urine samples | Changes occured :baseline , 4 weeks,and 8 weeks |
Assesment of Two Different Modalities of Maxillary Canine Retraction Assisted With Injectable Platelet Rich Fibrin

Study Overview
=================
Brief Summary
-----------------
The present prospective clinical study will be undertaken for assessment of two different modalities of maxillary canine retraction assisted with injectable platelet rich fibrin.

Official Title
-----------------
Assesment of Two Different Modalities of Maxillary Canine Retraction Assisted With Injectable Platelet Rich Fibrin: A Prospective Clinical Study

Conditions
-----------------
Effect of Platelet Rich Fibrin Tooth Movement

Intervention / Treatment
-----------------
* Biological: Injectable platelet rich fibrin .
* Biological: Injectable platelet rich fibrin .


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: An age range from 15-22 years. Severe crowding or protrusion requiring 1st premolars extractions followed by symmetrical canine retraction. All permanent teeth present, 3rd molars are excluded. Good oral and general health. No systemic disease/medication that could interfere with OTM. No previous orthodontic treatment. Exclusion Criteria: Patient diagnosed to have an indication for non-extraction approach. Poor oral hygiene or periodontally compromised patient. Patient with craniofacial anomalies or previous history of trauma, bruxism or parafunctions.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group I<br>will include 9 patients | Biological: Injectable platelet rich fibrin .<br>* i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.<br>|
| Active Comparator: Group II<br>will include 9 patients. | Biological: Injectable platelet rich fibrin .<br>* i-PRF that will be performed four times on intervention sides according to a standardized protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment of acceleration of canine retraction | rate of canine retraction | post interventional at 4 months |